Pyxis Oncology

Pyxis Oncology OCF Margin

The Operating Cash Flow Margin of Pyxis Oncology (PYXS) as of Oct 31, 2026 is -458.23 %. In the previous year, Operating Cash Flow Margin was -357.19 % — a change of 28.29% (lower).

OCF Margin

-458.23 %

YoY

28.29%

Last updated:

Operating Cash Flow Margin of Pyxis Oncology is 2025 -458.23 % . Operating Cash Flow Margin of Pyxis Oncology was 2024 -357.19 % . It decreases by 28.29% lower compared to the previous year.

The Pyxis Oncology OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2024
-357.19 USD
Jan 1, 2025
-458.23 USD
The Pyxis Oncology OCF Margin history
YEAROCF MarginYoY
-458.23 %+28.29%
-357.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pyxis Oncology Stock analysis

What does Pyxis Oncology do? Pyxis Oncology Inc develops a multi-modality portfolio of next-generation therapeutics targeting difficult-to-treat cancers, including antibody drug conjugate (ADC) product candidate PYX-201, immuno-oncology (IO) product candidate PYX-106, and monoclonal antibody (mAb) preclinical discovery programs. The company focuses on developing these as monotherapies and in combination with other therapies to improve patient quality of life. Its ADC product PYX-201 consists of an Immunoglobulin G1 (IgG1) anti-fibronectin Extradomain-B mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Pyxis Oncology is developing its product pipeline including PYX-107 as part of its portfolio. The company's revenue model is based on the development and potential future commercialization of its therapeutic candidates. Pyxis Oncology is focused on advancing its pipeline through clinical trials and regulatory approvals. The firm's product candidates are designed to address unmet medical needs in oncology, targeting specific cancer types through innovative mechanisms such as ADC and IO approaches. The company's portfolio includes PYX-201, PYX-106, and PYX-107 as key therapeutic candidates in various stages of development. Pyxis Oncology Inc is a biopharmaceutical company that develops therapeutics for difficult-to-treat cancers. Its product candidates include PYX-201, PYX-106, and PYX-107, each targeting specific cancer mechanisms. The company's development approach combines ADC, IO, and mAb technologies to create innovative cancer treatments. The firm's pipeline focuses on improving patient outcomes through novel therapeutic approaches in oncology. Pyxis Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pyxis Oncology stock

Operating Cash Flow Margin of Pyxis Oncology is -458.23 % in 2025.

Operating Cash Flow Margin of Pyxis Oncology changed from -357.19 % to -458.23 %, representing a 28.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Pyxis Oncology since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Pyxis Oncology with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pyxis Oncology

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pyxis Oncology